Press Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email link below.

Get News Alerts by Email

All Years		•
Search		
	Go	

Advanced Search

Nov 09 2022

BioLife Solutions Reports Third Quarter 2022 Financial Results

Record revenue of \$40.7 million increased 21% over Q3 2021; biopreservation media revenue growth of 50%, validating leading position as a critical cell and gene therapies tool supplier Cash flow...

Nov 02 2022

<u>BioLife Solutions to Report Third Quarter 2022 Financial Results and Provide Business</u> Update on November 9, 2022

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

Oct 11 2022

<u>CSafe and BioLife Solutions, Inc. announce partnership to expand supply chain solutions</u> <u>for the cell and gene therapy market</u>

CSafe joins BioLife's global partner network of cold chain solution providers using the evo® cold chain management platform MONROE, Ohio and BOTHELL, Wash., Oct. 11, 2022 /PRNewswire/ -- CSafe,...

Oct 03 2022

BioLife Solutions Announces COO to Retire and Join Board of Directors

Roderick de Greef retirement planned for January 2023 with appointment to BioLife Board of Directors Geraint Phillips to assume responsibilities in January 2023 as newly promoted Senior

Aug 25 2022

BioLife Solutions Appoints Cell Therapy Executive Timothy L. Moore to its Board of Directors

Industry veteran brings extensive technical operations scale-up experience and extreme fluency in cell therapy tools and services selection process BOTHELL, Wash., Aug. 25, 2022 /PRNewswire/ --...

Aug 09 2022

<u>BioLife Solutions Reports Second Quarter 2022 Financial Results and Updates Full Year 2022 Revenue Guidance</u>

Record revenue of \$40.5 million increased 30% over Q2 2021, with organic revenue growth of 44% and biopreservation media revenue growth of 46% Updating 2022 revenue guidance to \$160 million to...

Aug 02 2022

<u>BioLife Solutions to Report Second Quarter 2022 Financial Results and Provide Business Update on August 9, 2022</u>

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

lun 09 2022

<u>BioLife Solutions Deploys SciSafe's Ultra Low Controlled Temperature Trailers to Extend Domestic Cold Chain Services</u>

The new service will enable life sciences companies to seamlessly move hardware as well as biomaterials at the local level BOTHELL, Wash., June 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc....

May 09 2022

BioLife Solutions Reports First Quarter 2022 Financial Results

Revenue of \$36.2 million increased 115% over Q1 2021, with organic revenue growth of 45% and biopreservation media revenue growth of 53% Affirms 2022 revenue guidance of \$159.5 million to \$171.0...

May 09 2022

<u>BioLife Solutions Executes Co-Marketing Agreement with Coriell Institute for Medical</u>
<u>Research to Offer Biostorage, Biospecimen Processing and Custom Laboratory Services</u>

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

. ... ----

<u>BioLife Solutions to Report First Quarter 2022 Financial Results and Provide Business</u> <u>Update on May 9, 2022</u>

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

Apr 07 2022

BioLife Solutions, Inc. Announces Change of Auditor to Grant Thornton LLP

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT)...

Mar 18 2022

BioLife Solutions Receives Nasdag Notice of Noncompliance for Delayed 10-K Filing

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT)...

Mar 17 2022

BioLife Solutions Announces Additional Delay in Filing of Annual Report on Form 10-K

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT)...

Mar 15 2022

<u>BioLife Solutions Secures Strategic Customer Wins and Plans 2022 Expansion in \$400</u> <u>Million Biostorage Services Market</u>

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today provided...

Mar 01 2022

BioLife Solutions to Attend and Present at Upcoming Investor Conferences

Cowen presentation is scheduled for Wednesday, March 9th from 12:50-1:30pm ET in Track 12

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT)...

Feb 28 2022

BioLife Solutions Reports Unaudited Fourth Quarter and Full Year 2021 Financial Results Record quarterly revenue of \$37.3 million up 153% over Q4 2020, with organic revenue growth of 64% and biopreservation media revenue growth of 64%

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and

supplier of class-defining proproduction products and services for the cell and gene therapies (CGT)...

Feb 21 2022

<u>BioLife Solutions to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on February 28, 2022</u>

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

lan 10 2022

BioLife Solutions Announces Preliminary 2021 Revenue of \$119 Million, Up 148% Over 2020

Biopreservation Media Revenue of \$43 Million Increased 39% Over 2020

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced...

lan 04 2022

<u>BioLife Solutions Collaborates with Seattle Children's to Improve Viral Vector and Cell and Gene Therapy Manufacturing</u>

Sexton Cell Processing tools and CryoStor cGMP Freeze Media Incorporated in Cell and Gene Therapy Workflows

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets, today announced an...

Dec 16 2021

<u>UNICEF Selects Ultra-Low Temperature (ULT) Freezers from BioLife Solutions to Extend</u> Thermal Stability of COVID-19 Vaccines

Stirling Ultracold Freezers to be Used in Africa, the Middle East and South America

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

Nov 17 2021

BioLife Solutions Ranks 353 Among Fastest-Growing Companies in North America on the 2021 Deloitte Technology Fast 500™

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

Nov 15 2021

BioLife Solutions Named to Inc. Magazine Inaugural List of Best-Led Companies Number 200 out of 250; more than 10,000 companies profiled

Riol ife Solutions Inc. (Nasdag: RLFS) ("Riol ife" or the "Company"), a leading developer and

supplier of class-defining bioproduction products and services for the cell and gene therapies and the...

Nov 11 2021

BioLife Solutions Announces Third Quarter 2021 Financial Results


Total revenue up 200% over Q3 2020; organic revenue up 37% over Q3 2020 driven by 49% growth in media revenue

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the...

Nov 04 2021

BioLife Solutions Announces Executive Management Changes

BioLife Solutions, Inc. (the "Company") (Nasdaq: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets,...



 $\underline{https://investors.biolifesolutions.com/press-releases?l=25\&o=25}$